VNDA — what changed in the latest 10-Q
A section-by-section comparison of VNDA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-07 vs the prior 10-Q · 2025-10-30
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +106 | −137 | ~77 | 72 |
| Market risk (Item 3) | Text added/removed | +106 | −137 | ~77 | 71 |
| Controls & procedures | Text added/removed | +106 | −137 | ~77 | 71 |
| Legal proceedings | Text added/removed | +106 | −137 | ~77 | 71 |
| Risk factors | Some risk factors updated | +106 | −137 | ~77 | 71 |
| Other information | Text added/removed | +106 | −137 | ~77 | 71 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize BYSANTITM (milsaperidone) for bipolar I disorder and schizophrenia;
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•our ability to obtain approval from the FDA for NEREUSTM for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis;
•our dependence on third-party manufacturers to manufacture our commercial products in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of equity awards
Text removed vs the prior filing · source: 10-Q · 2025-10-30
•our ability to continue to generate United States (U.S.) sales of Fanapt® oral tablets for the treatment of schizophrenia;
•our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness;
•the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;
•our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality;
Issuance of common stock from the exercise of stock options and settlement of restricted stock units, net of shares withheld for taxes623,338 1 (916)— — (915)
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice